Treats major depressive disorder. ANDA 76690, held by Teva Pharmaceutical Industries. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 76690 (Venlafaxine Hydrochloride), held by Teva Pharmaceutical Industries, was first approved by FDA on Aug 3, 2006, with 17 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Venlafaxine tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2006 | Original application | Approved |
| Venlafaxine HydrochlorideEQ 25MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 50MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 100MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 30Labeling · Standard review | Approved | None posted |
| Aug 9, 2023 | Supplement 29Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 27Labeling · Standard review | Approved | None posted |
| Apr 14, 2020 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 20Labeling · Standard review | Approved | |
| Jun 30, 2014 | Supplement 18Labeling · Standard review | Approved | None posted |
| Sep 19, 2012 | Supplement 17Labeling · Standard review | Approved | None posted |
| Aug 4, 2010 | Supplement 15Manufacturing | Approved | None posted |
| Mar 15, 2010 | Supplement 16Labeling | Approved | None posted |
| Jul 22, 2009 | Supplement 14Labeling | Approved | None posted |
| Jan 27, 2009 | Supplement 11Labeling | Approved | None posted |
| Aug 13, 2008 | Supplement 10Labeling | Approved | None posted |
| Aug 13, 2008 | Supplement 8Labeling | Approved | None posted |
| Feb 5, 2008 | Supplement 6Labeling | Approved | None posted |
| Feb 5, 2008 | Supplement 5Labeling | Approved | None posted |
| Jul 12, 2007 | Supplement 3Labeling | Approved | None posted |
| Aug 3, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters